The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction

J Clin Lipidol. 2021 Jan-Feb;15(1):33-60. doi: 10.1016/j.jacl.2020.12.005. Epub 2020 Dec 11.

Abstract

An Expert Panel of the National Lipid Association reviewed the evidence related to the use of coronary artery calcium (CAC) scoring in clinical practice for adults seen for primary prevention of atherosclerotic cardiovascular disease. Recommendations for optimal use of this test in adults of various races/ethnicities, ages and multiple domains of primary prevention, including those with a 10-year ASCVD risk <20%, those with diabetes or the metabolic syndrome, and those with severe hypercholesterolemia were provided. Recommendations were also made on optimal timing for repeat calcium scoring after an initial test, use of CAC scoring in those taking statins, and its role in informing the clinician patient discussion on the benefit of aspirin and anti-hypertensive drug therapy. Finally, a vision is provided for the future of coronary calcium scoring.

Keywords: Atherosclerotic cardiovascular disease risk prediction; Computed tomography; Coronary artery calcium scoring; Subclinical coronary atherosclerosis.

MeSH terms

  • Adult
  • Calcium*
  • Coronary Vessels*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Risk Assessment
  • Vascular Calcification

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Calcium